Cadila receives USFDA approval for Ibrutinib tablets

The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.

Jul 22, 2021 05:07 IST India Infoline News Service

Cadila Healthcare
Zydus Cadila, listed as Cadila Healthcare, has received tentative approval from the USFDA to market Ibrutinib Tablets, in the strengths of 140 mg, 280 mg, 420 mg and 560 mg (US RLD: Imbruvica Tablets).

Ibrutinib belongs to a class of drugs are known as kinase inhibitors and is used to treat certain cancers, such as mantle cell lymphoma or marginal zone lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, and Waldenstrom's macroglobulinemia.

The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.

The group now has 319 approvals and has so far filed over 400 ANDAs since the commencement of the
filing process in FY 2003-04.

On Sensex, Cadila finished at Rs622 per piece flat compared to the previous closing. 

Related Story

Open Free Demat Account (Rs699)